<DOC>
	<DOCNO>NCT01962428</DOCNO>
	<brief_summary>It design test hypothesis high loading dose ( 360mg ) ticagrelor versus conventional loading dose ( 180mg ) result high inhibition platelet aggregation ( IPA ) without increase bleed event .</brief_summary>
	<brief_title>Different LD Ticagrelor Antiplatelet Effect Patients With Non-ST-segment Elevation ACS Undergoing PCI</brief_title>
	<detailed_description>After provide write informed consent , patient randomize receive ticagrelor 360mg 180mg loading dose ( LD ) , 90mg bid maintenance dose start 12 hour LD.PCI perform 2h-72h give load dose.All patient receive acetylsalicylic acid ( ASA ) 75 100 mg daily unless intolerant.IPA 0 , 0.5 , 1 , 2 , 8 , 24h load dose ticagrelor measure . CK-MB , troponin I , myoglobin , CRP detect 0h , PCI , 8h PCI , 24h PCI . ECG conduct 0h within 24h PCI . Patients return 28 day follow-up visit load dose ticagrelor , documented adverse event .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision inform consent prior study specific procedure . Male nonpregnant female ; age 18 80 year old . Patients nonSTsegment elevation acute coronary syndrome schedule undergoing PCI . Any contraindication use ticagrelor . On treatment P2Y12 receptor antagonist past 30 day . Known allergy aspirin ticagrelor . On treatment oral anticoagulant ( Vitamin K antagonist , dabigatran , rivaroxaban ) . Known blood dyscrasia bleed diathesis . STsegment elevation acute myocardial infarction . NonST segment elevation acute coronary syndrome highrisk feature warrant emergency coronary angiography . Left ventricular ejection fraction â‰¤30 % ; renal failure creatinine 3 mg/dl ; history liver disease ; increase risk bradycardia , concomitant therapy drug interfere CYP3A4 metabolism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>ticagrelor</keyword>
	<keyword>load dose</keyword>
	<keyword>non-ST-segment elevation acute coronary syndrome</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>antiplatelet effect</keyword>
	<keyword>bleed event</keyword>
	<keyword>major adverse cardiac event</keyword>
</DOC>